What’s the problem?
Currently it is difficult to know for sure whether a woman with ovarian cancer will benefit from surgery. Sometimes surgery can be carried out on women who do not benefit from it, but instead their quality of life is reduced even further by unnecessary surgery that does not improve their chances of survival.
- Aim: To identify how the biology of ovarian tumours affect how effective surgery is in removing ovarian cancer. And to map what makes tumours unique to see how they respond to platinum-based chemotherapy. Professor Fotopoulou is also exploring the development of new medical devices and engineering collaborations.
- Lead: Dr Euan Stronach
- Scientists funded by Ovarian Cancer Action: Dr Euan Stronach and Proffesor David Bowtell
What’s the science?
- Not all surgery is the same, it can be affected by the expertise of the surgeon and their access to resources
- Not all tumours are the same, and all patients are unique individuals
- In order to look at the biology of tumours and how different tumours respond to surgery – without the investigation being affected by variable surgery quality - patients in the study need to be treated to the same surgical standard
- The team want to identify individual markers on chromosomes in tumours that can predict a woman’s chances of survival after maximal effort surgery
How will this affect ovarian cancer treatment?
The team want to know how to best integrate knowledge of the biology of tumours with surgical effort in order to create personalised and optimised treatment of advanced ovarian cancer.